Organogenesis Holdings Inc.

Total Valuation

Organogenesis Holdings Inc. carries a market capitalization of 220.03M, placing it among publicly traded companies globally. Its enterprise value stands at 473.40M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Organogenesis Holdings Inc. currently has 128.67M shares outstanding.

Valuation Ratios

Organogenesis Holdings Inc. trades at a trailing price-to-earnings ratio of 25.06. The price-to-sales ratio is 0.68, and the price-to-book ratio stands at 2.11.

Enterprise Valuation

On an enterprise value basis, Organogenesis Holdings Inc. trades at an EV/EBITDA multiple of 43.55 and an EV/FCF ratio of 10.98. The EV/Sales ratio of 1.04 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 821.92 provides insight into valuation relative to core operating earnings.

Financial Position

Organogenesis Holdings Inc. maintains a current ratio of 3.52, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Taxes

Over the trailing twelve months, Organogenesis Holdings Inc. has paid 49.39M in income taxes, reflecting an effective tax rate of 31.10.

Stock Price Statistics

Organogenesis Holdings Inc.'s stock has declined approximately -64.15094% over the past 52 weeks. The 50-day moving average sits at 2.17, while the 200-day moving average is 3.10.

Income Statement

Over the trailing twelve months, Organogenesis Holdings Inc. generated 454.61M in revenue and converted that into -84.16M in net income, yielding earnings per share of -0.65. EBITDA reached -1.24M, while operating income came in at -34.19M.

Balance Sheet

Organogenesis Holdings Inc. holds 46.10M in cash and equivalents against 66.95M in total debt, resulting in a net debt position of -46.10M. Total book value stands at 148.27M, with working capital of 143.34M providing operational flexibility.

Cash Flow

Organogenesis Holdings Inc. produced 31.97M in operating cash flow over the past twelve months. After subtracting -11.13M in capital expenditures, free cash flow totaled 20.84M - equivalent to 0.16 per share.

Margins

Organogenesis Holdings Inc. operates with a gross margin of 70.17, reflecting its pricing power and cost economics. The operating margin of -7.52 and net profit margin of -18.51 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of 11.81 indicates the proportion of earnings distributed to shareholders.

Scores

Organogenesis Holdings Inc. posts an Altman Z-Score of 2.39, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.